Cargando…
Cellular immunotherapy for medulloblastoma
Medulloblastoma (MB) is the most common malignant brain tumor in children, making up ~20% of all primary pediatric brain tumors. Current therapies consist of maximal surgical resection and aggressive radio- and chemotherapy. A third of the treated patients cannot be cured and survivors are often lef...
Autores principales: | Schakelaar, Michael Y, Monnikhof, Matthijs, Crnko, Sandra, Pijnappel, Emma W, Meeldijk, Jan, ten Broeke, Toine, Bovenschen, Niels |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076947/ https://www.ncbi.nlm.nih.gov/pubmed/36219688 http://dx.doi.org/10.1093/neuonc/noac236 |
Ejemplares similares
-
Immunotherapy in Medulloblastoma: Current State of Research, Challenges, and Future Perspectives
por: Voskamp, Marije J., et al.
Publicado: (2021) -
Noncytotoxic functions of killer cell granzymes in viral infections
por: de Jong, Lisanne C., et al.
Publicado: (2021) -
Intracellular and Extracellular Roles of Granzyme K
por: Bouwman, Annemieke C., et al.
Publicado: (2021) -
Pediatric medulloblastoma express immune checkpoint B7-H3
por: Li, S., et al.
Publicado: (2022) -
Immunotherapy for Medulloblastoma: Current Perspectives
por: Kabir, Tanvir F, et al.
Publicado: (2020)